Velomedix is a Menlo Park, California–based development-stage medical device company focused on advancing therapeutic hypothermia to treat ischemic and reperfusion injuries from cardiac arrest, heart attack (AMI), stroke, and trauma. Its technology aims to achieve rapid, user-friendly cooling to ~33°C within hospital time-to-treatment standards. The company completed the CAMARO clinical trial in the EU, which the announcement says demonstrated unprecedented positive neurologic outcomes versus published clinical data. Velomedix closed a $10.2 million Series B financing to fund regulatory and commercialization steps. Proceeds will be used to initiate a post‑CE Mark trial to support EU commercialization and to obtain U.S. FDA approval to run a clinical study in the United States. The company concurrently strengthened its leadership team, appointing Jeffrey Gold as President & CEO and Michael Moore as Vice President of Operations. Velomedix emphasizes its platform’s potential to broaden hypothermia treatment into larger patient groups including AMI and stroke.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Feb 2012